July 18, 2006 -- Crucell stopped development of a vaccine for a cystic fibrosis infection after the vaccine failed a trial; Astellas abandoned an Alzheimer’s disease drug when it was not effective; Cortex is on track with its pre-clinical studies for Ampakine compound CX717, currently on FDA hold; Theravance out-licensed the Japanese rights of its antibiotic, telavancin, to Astellas; MedImmune will take four weeks to respond to the FDA’s questions about its new FluMist vaccine; Myriad Genetics said Flurizan reduced the number of psychiatric episodes in Alzheimer’s patients; Cadence Pharma filed with the SEC for its IPO; AstraZeneca requested FDA approval of a long-acting form of Seroquel; Cell Genesys expanded the Phase I trial of its recurrent bladder cancer drug; Novavax reported good preclinical results from several potential flu vaccines; and Nabi reported that PhosLo outperformed Renagel. The Centient Biotech 200™ was 5 points lower at 3494.75, a loss of .15%. More details...
